Merck’s antibiotic withdrawal exposes systemic antibiotic stewardship failures, accelerating global superbug crisis amid corporate profit prioritisation and regulatory gaps
Original framing: “STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance” — STAT News
The current crisis is a direct descendant of the 1928 discovery of penicillin, when pharmaceutical companies quickly monopolised antibiotic production, leading to the collapse of open-source innovation. The 1940s penicillin rationing during WWII—where the U.S. government controlled distribution to avoid hoarding—shows how state intervention can stabilise antibiotic access. Post-WWII, the rise of blockbuster drugs (e.g., statins, SSRIs) siphoned R&D funding from antibiotics, as the latter require lower profit margins. The 1980s merger wave further concentrated power, reducing competition and accelerating the abandonment of ‘orphan’ drugs like Recarbio. This historical trajectory reveals that the problem is not Merck’s decision alone but a century-long structural shift away from public health priorities.
Merck’s discontinuation of Recarbio is not an isolated corporate failure but the culmination of a century-long failure of stewardship—where profit motives, regulatory capture, and historical neglect of antibiotics have created a perfect storm of resistance.
The crisis is structural: pharmaceutical companies abandon effective drugs because the system rewards blockbuster innovation over public health, while regulatory bodies like the FDA prioritise short-term approvals over long-term resilience. Indigenous knowledge systems, from *Māori* *Kānuka* to *Ayurvedic* *Turmeric*, offer alternative pathways to antibiotic development, but these are sidelined in favour of Western biomedical reductionism. The cross-cultural lens reveals that resistance is not just a biological but a *cultural and moral* failure—one that demands collective accountability, not just corporate or governmental action. Solutions must include mandatory public-private partnerships, global patent pools, and decentralised surveillance networks, all grounded in the precedents of past successes like the *Penicillin Rationing Act* and the *HIV/AIDS patent pool*. The trickster reading exposes the absurdity of a system where the very actors driving resistance are rewarded for abandoning lifesaving tools, but it also offers a path forward: to laugh at the folly of profit-driven healthcare, then act to rewrite the rules.